Mabwell (SSE: 688062) is an innovation-driven biopharmaceutical company with an entire industry chain of R&D, manufacturing, and commercialization. Consistent with our commitment to provide more effective and accessible therapies and innovative products, Mabwell has worked to fulfill global medical needs and bring life-changing solutions to patients.
Mabwell Established a Licensing and Commercialization Agreement of Adalimumab Biosimilar for Argentina Market
Good Safety Profile and Antitumor Activity: Oral Presentation of Mabwell’s 9MW2821 at 2023 ESMO
Mabwell Announces Latest Clinical Progress and Data to be Reported on ESMO 2023 of 2 Novel Drugs
Mabwell Announces First Patient Dosed in Phase Ib/II Trial of its Novel Nectin-4 Targeting ADC in Combination with PD-1 Inhibitor
Mabwell Partners with Legrand to Market Denosumab Biosimilars in Colombia and Ecuador